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ABSTRACT
Objective: To identify and follow a series of 52 patients with optic neuropathy related to
sarcoidosis.
Methods: Prospective observational cohort study.
Results: The disorder was more common in women and affected a wide age range. It was proportion-
ately more common in African and Caribbean ethnic groups. Two clinical subtypes were identified:
the more commonwas a subacute optic neuropathy resembling optic neuritis; a more slowly progres-
sive optic neuropathy arose in the remaining 17%. Sixteen (31%) were bilateral. Concurrent intra-
ocular inflammation was seen in 36%. Pain arose in only 27% of cases. An optic perineuritis was
seen in 2 cases, and predominate involvement of the chiasm in one. MRI findings showed optic nerve
involvement in 75% of cases, with adjacent and more widespread inflammation in 31%. Treatment
with corticosteroids was helpful in those with an inflammatory optic neuropathy, but not those with
mass lesions. Relapse of visual signs arose in 25% of cases, necessitating an increase or escalation
of treatment, but relapse was not a poor prognostic factor.
Conclusions: This is a large prospective study of the clinical characteristics and outcome of treat-
ment in optic neuropathy associated with sarcoidosis. Patients who experience an inflammatory
optic neuropathy respond to treatment but may relapse. Those with infiltrative or progressive
optic neuropathies improve less well even though the inflammatory disorder responds to
therapy. Neurol Neuroimmunol Neuroinflamm 2016;3:e270; doi: 10.1212/NXI.0000000000000270
GLOSSARY
ACCESS 5 A Case Control Etiologic Study of Sarcoidosis; ACE 5 angiotensin-converting enzyme.
Sarcoidosis forms a spectrum of autoinflammatory disorders of unknown etiology characterized
by the development of immune activation leading to an immunologic cascade that results in an
inflammatory infiltration of tissues, with granuloma formation and later fibrosis. Any tissue can
be affected, but the lungs, skin, liver, and joints are particularly affected.1
The disorder is more common in women than in men and is predominately a disease of
young adulthood but affects all age groups.2,3 In the United States, there is a higher prevalence
in African Americans, and the disease may be more severe in this ethnic group.2,4
Ophthalmic complications of the disease arise in some 10% to 50%,5–7 with 12% in
ACCESS (A Case Control Etiologic Study of Sarcoidosis)2; not all patients show the character-
istics of a granulomatous uveitis.8 Anterior uveitis is the most common, with mutton fat keratic
precipitates and Koeppe iris nodules, and vitritis leading to the string of pearls, periphlebitis,
candle wax drippings, and choroidal involvement.5–11 The development of keratoconjunctivitis
sicca appears to be almost inevitable. The prognosis for visual recovery in those with intraocular
inflammation is in general good9–11 with correct treatment.
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Involvement of the nervous system is
uncommon, and accounts for 5% to 10% of
published retrospective series.12 It may arise
at any point during the disease, and all regions
of the nervous system may be affected.
In this report, we describe the results of
a clinical study conducted over the course of
20 years in which we characterize the clinical
syndromes, concomitant systemic features,
investigation results, and response to appropri-
ate treatment in a prospectively acquired
group of patients seen and treated at 3 large
teaching hospitals in London.
METHODS All patients seen and assessed in our neuroophthal-
mology departments with visual disorders are investigated to iden-
tify the cause and to define the most appropriate treatment. This
investigation includes a series of blood investigations and imaging;
when these investigations found no evidence for a demyelinating
disorder (through MRI features principally), systemic autoimmune
condition (e.g., antinuclear antibodies, DNA, aquaporin-4, and
myelin oligodendrocyte glycoprotein antibodies), or infectious or
metabolic causes, a granulomatous cause was considered, and
further investigations were undertaken. Those in whom systemic
features of sarcoidosis were identified during investigation and those
already known to have active systemic sarcoidosis, in whom the
diagnosis of a granulomatous optic neuropathy was considered by
the authors to be highly probable,13 were recorded prospectively
and included in the study. The records were kept according to data
protection regulations in the neuroophthalmology departments and
collated by 2 of us (B.J.B. and D.P.K.).
Criteria for the diagnosis of sarcoidosis involved histologic
proof (in 40 cases) of a granulomatous disorder currently active
or requiring continuing treatment or (in 12 cases) adequate proof
on clinical grounds that no alternative explanation existed for the
systemic disorder in the minds of the treating physicians: for
example, clear radiologic evidence for lung and mediastinal
involvement together with clear evidence for another characteris-
tic feature of the disease, such as hypercalcemia, raised serum
angiotensin-converting enzyme (ACE) or other tissue involve-
ment, associated with a typical pattern of isotope uptake using
gallium scintigraphy or PET. Seventeen cases in whom these cri-
teria were unfulfilled were excluded from the data analysis.
Group data were compared with the Fisher exact test and
Mann–Whitney test.
Standard protocol approvals, registration, and patient
consents. Ethical approval for the study was obtained, and
patients gave informed consent to be included.
RESULTS Demographics. Fifty-two patients were
included in the study. The mean (range) age was
42.5 (20–71) years. Thirty-two (61%) were women.
Twenty-four were Caucasian, 24 African or Caribbean,
and 4 were from South Asia.
Clinical features of the systemic disorder. The diagnosis
of systemic sarcoidosis was made concurrently in 33
patients and in one subsequently. The remaining 18
had already been diagnosed, between 6 months and
20 years before the onset of the optic neuropathy.
A histologic diagnosis was made from respiratory
tissue (transbronchial or mediastinal lymph gland
biopsy) in 28 cases, lymph gland biopsy in 3, liver
biopsy in 1, orbital biopsy in 3, and neurologic tissue
in 5. All fulfilled the criteria for the “highly probable”
diagnosis of the WASOG (World Association of
Sarcoidosis and Other Granulomatous Diseases) Sar-
coidosis Organ Assessment Instrument.13 In 12 cases,
the diagnosis had been deemed secure on clinical
grounds by the treating respiratory physicians, with
clear evidence on clinical grounds for a multisystem
disorder typical of sarcoidosis as noted in the methods
section above; these were all patients presenting with
an optic neuropathy already diagnosed with systemic
sarcoidosis.
The predominate systemic clinical syndrome was
respiratory in 38 cases, the orbit and lacrimal glands
in 6, cervical lymph glands in 4, the skin in 3, the nose
and sinuses in 3, and the liver and joints in 1 each. Tis-
sue involvement outside of the nervous system was
multisystem in 17 cases. The serum ACE was elevated
in 24 (57%) of available data at the time of onset of the
optic neuropathy; the median serum ACE was 111
(18–205) U/L (normal range 8–50 U/L).
Gallium scans were undertaken in 10 instances, in
which 1 was normal, 6 showed a “panda” pattern of
uptake in the lacrimal and parotid glands, 1 a “lambda”
pattern of mediastinal uptake, and 2 a combination of
both patterns.
Clinical characteristics of the optic neuropathy. All
patients presented with symptoms and signs of an
optic neuropathy, defined as a reduction in central
visual acuity and color vision, reduction in the visual
field, and when seen, an abnormality of the pupillary
response. Patients with a subacute optic neuropathy
that evolved over days were considered separately
from those with a more progressive clinical course,
in which the symptoms evolved over weeks. The for-
mer were considered to show an optic neuritis syn-
drome, the latter a progressive syndrome.
Forty-three cases showed an optic neuritis syn-
drome, of which 27 were unilateral. Twelve of the
bilateral cases showed a sequential optic neuropathy
with a range of latency between the 2 episodes of
1 to 60 months. A bilateral optic neuropathy arose
synchronously in 4 cases (figure 1). The median
(range) acuity at presentation was 0.05 (0–1.0) in
unilateral cases and 0.13 (0–1.0) in bilateral involve-
ment. Pain was a feature in 27% of cases overall.
A wide range of visual field defects was noted;
most had central or centrocecal scotomas, but hemi-
anopic and altitudinal defects were also seen.
The chiasm was involved in one case. A unilateral
optic perineuritis arose in 2 cases. A progressive unilateral
optic neuropathy was the presenting feature in 6 cases.
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Table 1 shows the important clinical features in
each of the subgroups noted.
Coexistence of inflammatory ocular disease. Intraocular
inflammation was seen at the same time as the optic
neuropathy in 19 cases (36%): a granulomatous ante-
rior uveitis was seen in 10 cases, an isolated vitritis in
1, a panuveitis in 1, isolated choroidal involvement in
1, features of a retinal vasculitis in 2, cotton wool spots
in 2, macular exudates in 1, and episcleritis in 1. In no
case was the intraocular disease longstanding and asso-
ciated with chronic glaucoma or retinal ischaemia.
Neurologic investigation results: Imaging. One patient
underwent CT; the remainder had MRI studies of the
orbits and brain, of which 13 were adjudged to be nor-
mal. Twenty patients had abnormalities restricted to the
optic nerve or sheath, of whom 14 showed enhance-
ment of the optic nerve and sheath (figure 1) with
intrinsic lesions of one or both optic nerves, while the
remainder showed high signal within the nerve without
enhancement. In addition, 3 cases (and the one who had
CT) showed intrinsic lesions within the nerve and thick-
ening of the adjacent optic nerve sheath complex. The
chiasmal lesion was associated with enhancement of the
chiasm extending forward into one of the nerves.
Both patients with a perineuritis showed features
of this, i.e., the predominate feature was of enhance-
ment and thickening of the sheath, not the whole
complex (figure 2).
A minority of patients whose clinical syndrome was
one of a subacute optic neuropathy resembling an optic
neuritis showed additional imaging features of more
widespread involvement of the nervous system by the
disease: 8 patients with unilateral optic neuropathies
and 2 with bilateral involvement showed high signal
within the nerves, enhancement of the complex, which
also involved the orbital apex (5 cases) (figure 3A), the
floor of the middle cranial fossa (4 cases) (figure 3B),
and the frontal lobes (1 case).
In general, the initial acuity was better in those
with normal imaging and no enhancement than in
those in whom enhancement was seen (figure 4).
Figure 1 MRI in subacute optic neuritis caused by sarcoidosis
MRI showing (A) swelling and high signal within the nerve, and (B) enhancement in a patient who presented with a painless
subacute optic neuropathy to no perception of light over 5 days. With oral corticosteroid treatment, she recovered to 6/6
(20/20, 1.0). Azathioprine was added and oral steroids withdrawn over 6 months. She has remained well since.
(C) T1-weighted axial MRI showing swelling and enhancement of the anterior half of the left optic nerve. (D, E) T1-weighted
coronal MRI showing 2 other cases in which the nerve is seen to be swollen and enhancing following administration of con-
trast. Each case had a subacute optic neuritis with improvement after administration of corticosteroids.
Table 1 Clinical characteristics and ocular findings at presentation in the 52
patients studied
Nadir visual
acuity
Pain
Disc
Ocular
inflammation
<0.25 ‡0.25 Swollen Pale Normal Anterior Posterior
Unilateral 17 10 9 12 9 6 6 6
Bilateral synchronous 4 0 0 1 2 1 2 1
Bilateral sequential 8 4 2 3 4 5 3 1
Chiasmal 1 1
Perineuritis 2 1 1 1
Progressive 5 1 2 6 1
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Those whose clinical syndrome was of a progressive
optic neuropathy (6 cases) all showed meningeal
enhancing lesions that had formed masses, in each case
at the intracranial portion of the orbital apex (figure 3).
Neurologic investigation results: CSF. CSF results were
available in 33 cases, including 2 with mass lesions and
one with perineuritis. Twenty-five had normal CSF.
Seven (21%) showed CSF protein levels greater than
0.6 g/dL (median 0.95 g/dL, range 0.79–1.92). Five
(15%) showed a leukocyte pleocytosis (.5 cells/cm3)
(median 19, range 6–70). Twenty-eight (85%) had no
oligoclonal bands, and 5 showed matched bands in both
CSF and serum.
Treatment. Patients were treated in an individual way
in 3 different hospitals so there was a wide range of
medications, dosage regimens, and treatment dura-
tions. Forty-nine were treated with corticosteroids, of
whom 14 commenced with IV methylprednisolone
followed by oral prednisolone, while the remainder
received treatment with oral steroids from the outset.
The daily dose of prednisolone varied between 30
and 80 mg per day. The duration of treatment
varied greatly (4–320 weeks).
Eighteen were treated with immunosuppression:
12 from outset, and 6 upon relapse. Twelve received
azathioprine, 1 mycophenolate, and 5 methotrexate.
Two received tumor necrosis factor a antagonists,
for neurosarcoidosis in each case.
Follow-up. The median (range) length of follow-up
was 8 (0–20) years. The median (range) change in
visual acuity (defined as the best acuity following
treatment, even after relapse) was 10.46 (20.01 to
11.22) in bilateral cases and 10.175 (20.05 to
11.25) in unilateral cases. The median final acuity
in these 2 groups was 0.7 (0–1.25) and 0.5 (0–1.25).
Those with a subacute syndrome showed a median
improvement of 10.225 (range 20.01 to 11.22).
Those in the progressive subgroup showed no
improvement in visual acuity with treatment
although in each case there was resolution of menin-
geal enhancement over time.
While there was a suggestion that MRI abnormal-
ities at onset (figure 4) correlated with nadir acuity
and an improvement following treatment, this was
not significant (p . 0.3).
Considering treatment in those without a progres-
sive disease course or perineuritis, 12 were treated
Figure 2 MRI in optic perineuritis
(A) Inflammatory lesion within the orbit encasing the right optic nerve. The lesion was biopsied and granulomatous inflam-
mation identified. The optic neuropathy improved with steroids. (B, C) Optic perineuritis: T1-weighted axial and coronal MRI
showing enlargement of and enhancement of the optic nerve and its sheath throughout its entire length. This was the pre-
senting feature of the disease, which was diagnosed subsequently on histologic analysis of a cervical lymph node.
Figure 3 MRI of compressive optic neuropathy caused by dural lesions in
sarcoidosis
(A, B) Orbital apexmass with a progressive painful optic neuropathy and sarcoidosis of the lungs,
mediastinum, and heart. (C, D) Two cases of progressive optic neuropathy with strikingmeningeal
enhancement and swelling to formmass lesions. Despite intensive treatmentwith corticosteroids
and immunosuppression, neither case showed a meaningful improvement in visual acuity.
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with IV then oral steroids; median (range) acuity was
0.02 (0–1) and increased to 0.75 (0.02–1), median
change 10.3, and those treated with oral steroids at
onset 0.1 (0–1) increasing to 0.75 (0–1.25), and
median change 10.5 (p 5 0.77).
Relapse arose in 13 cases. For the most part, this
occurred early on; for example, patients treated with
60 mg prednisolone developed recurrence of symp-
toms and signs at 40 to 20 mg, and the signs settled
with an escalation of treatment. Immunosuppressive
agents were added in 7 cases—azathioprine in 4
and mycophenolate and methotrexate in one each.
The patient treated with methotrexate had had
repeated relapses, which stopped on the immunosup-
pressive drug. One patient had an intracranial relapse
of neurosarcoidosis and her optic neuropathy wors-
ened; she was treated with cyclophosphamide then
infliximab.
In those who relapsed, the improvement in acuity
following treatment was 10.25 (20.15 to 1 1.2),
and relapse did not appear to influence the outcome
in any way.
Patients with an isolated optic neuritis, raised serum
ACE, but no evidence for sarcoidosis. We have seen 6
additional patients who presented with an optic neu-
ritis and were found during investigation to have
a raised serum ACE (median 100 [range 80–178]
U/L). The clinical syndrome was not different from
the others described above; half were Caribbean, half
Caucasian, and half were bilateral. All were male. None
had pain. Two had a concurrent vitritis and one had
a granulomatous anterior uveitis. The median (range)
acuity in each eye was 0.1 (0–1.0). In each case, the
affected discs were seen to be swollen.
Imaging was normal in 3 and showed high signal
within the affected nerve in the other 3. CSF in 4 cases
showed normal protein and negative oligoclonal
bands in 3; in the other case, matched serum and
CSF bands were found. In this case, there was
a CSF lymphocytosis of 63 per cubic centimeter.
The others were acellular. Four had gallium scans
and each of these was normal.
One was considered to have a disc granuloma and
was watched without treatment; he improved over
2 years. The others received steroids and each improved
to 6/6 (1.0) vision.
These cases have been followed and none has
developed further or recurrent neurologic or systemic
symptoms. They appear to have neither sarcoidosis
nor multiple sclerosis.
DISCUSSION This work forms the largest series of
patients with optic neuropathy in sarcoidosis identi-
fied and each has been followed prospectively. The
age range was wide but the condition was more prev-
alent in the first half of life. The majority of patients
were women and there were equal numbers in Cauca-
sian and African or Caribbean ethnic groups. Accord-
ing to the epidemiologic findings in ACCESS, the
ethnic subgroups in London are 60% Caucasian,
14% African and Caribbean, and 18% South Asian,
and our results therefore suggest a greater prevalence
of the disease in African and Caribbean people who
live in London.
In general, the clinical syndrome resembled an optic
neuritis,14 although in some, the disease course was
more slowly progressive. Pain was a less prevalent fea-
ture than is seen in demyelinating optic neuritis, and
the median visual acuity at nadir was equivalent,
although more were no perception of light (table 2).
However, none of the features observed was specific to
sarcoidosis in this series. Sixty-four percent had a uni-
lateral involvement, 28% presented at a later time with
involvement of the second eye, while synchronous
bilateral involvement was less common (9%). It is
Figure 4 Histogram
Histogram showing the relationships between MRI features at onset/diagnosis (abscissa)
and initial (nadir) visual acuity then best acuity after treatment (ordinate).
Table 2 Comparison of clinical features with
results of the ONSG14
Present study ONSG
Mean acuity (range) 0.25 (1–0) 0.25 (1–0)
‡0.5 21 34
0.5–0.1 37 28
<0.1 28 36
NPL 11 3
Pain 27 90
Disc swelling 37 35
Ocular involvement 36 3
Abbreviation: NPL 5 no perception of light; ONSG 5 Optic
Neuritis Study Group.
Data are presented as percentages unless otherwise
indicated.
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noteworthy that there was evidence for concurrent intra-
ocular inflammation in only a minority of cases. Pre-
dominately this was mild (although more severe cases
had been excluded because of the uncertainty of the
pathogenesis of the optic neuropathy). Indeed, in
64% of patients, there was no history of ocular involve-
ment at any stage of the disease to date. Imaging showed
clear abnormalities, which accounted for the clinical
features in 75% of cases. The majority showed high
signal within the nerve, with or without enhancement.
Spontaneous improvement occurred (as has been
noted previously15,16), although the majority of pa-
tients were treated with steroids. Following this, an
often substantial improvement in vision took place,
even after several weeks without treatment. There was
no relationship between nadir acuity and final acuity.
Relapse occurred in 25% of cases, necessitating re-
commencement or an escalation of treatment, and
in the majority, this occurred early, as steroids were
withdrawn. Relapse itself was not a marker of poor
visual outcome. Repeated relapse was treated success-
fully with addition of immunosuppression.
Six cases (11%) had a more progressive disease
course and were shown to have a more widespread neu-
rologic involvement, each showing evidence for adja-
cent meningeal inflammation. Visual outcome in this
subgroup was poor, even though the disease process
required, in general, a higher and more prolonged dose
of steroids, concurrent immunosuppression, and in 2
cases, a requirement for biological agents with refrac-
tory disease. Evidence for neurosarcoidosis defined as
the presence of intracranial meningeal enhancement
arose in 16 cases overall—all of those with a progressive
course and 10 with a subacute course.
Involvement of the optic nerve in sarcoidosis may
arise through a variety of mechanisms: inflammation
of the nerve itself,15,17–19 compression or infiltration by
an inflammatory mass adjacent to the anterior visual
pathway (e.g., the orbital apex or pituitary gland),19,20
secondary involvement through ischemic complications
of retinal and choroidal inflammation and glaucoma,5–11
granulomas within the disc itself,17,20 meningeal inflam-
mation within the optic nerve sheath leading to an optic
perineuritis,21 and finally as a consequence of hydro-
cephalus.22 Optic neuropathy is not common in sar-
coidosis. It was seen in 5% of one series of 202
patients with ocular disease in sarcoidosis,23 but only
one in a series of 649 patients with systemic sarcoidosis24
and none in another of 285.25 In the literature before
2000, 57 cases had been published, of which 35
involved the optic nerve itself, 9 compression due to
an intracerebral lesion, 6 due to hydrocephalus, and 6
due to the complications of uveitis.26 Many noted that
bilateral involvement occurred and that imaging showed
enlargement of the optic nerve–sheath complex.19,21,27
Others15 noted that the acuity was lower than that seen
in a demyelinating optic neuritis. More recent series
from the United States have studied larger patient num-
bers. One study27 described 24 cases with optic neurop-
athy: 71% had not been known previously to have
systemic sarcoidosis and 42% showed previous or cur-
rent intraocular inflammation. The clinical features
were very similar to those in our series. Another28
showed that 14 of 67 patients known to have neurologic
sarcoidosis had some form of optic neuropathy.
We have identified a small subgroup of patients in
whom the serum ACE is elevated at presentation and
then subsequently normalizes without relapse. On fur-
ther investigation, these patients do not have sarcoidosis
and on follow-up show no sign of transformation into
a more widespread disease. The serum ACE appears
to increase in a nonspecific way and appears not to indi-
cate a systemic granulomatous disease. It is important to
identify this subgroup, which requires no additional
treatment, merely close follow-up and observation.
This large series of patients with optic neuropathy
in conjunction with sarcoidosis has shown that more
than half are not previously diagnosed with sarcoido-
sis, only a third have concurrent intraocular inflam-
mation, and the clinical characteristics and in most
cases the imaging features are not substantially differ-
ent from that seen in a regular demyelinating optic
neuritis. However, patients should be identified early
because the response to treatment may lessen with
time, and the identification of more widespread dis-
ease, particularly within the nervous system, will
require prolonged, often high-dose treatment with
steroids, immunosuppressive drugs, and modern bio-
logical therapies. Modern imaging investigations
including PET may make identification of these cases
easier, but a high index of clinical suspicion is still
important, particularly in non-Caucasian patients
presenting with a painless optic neuritis.
Once identified, we recommend that patients be
treated with high-dose (oral or IV) corticosteroids,
followed by a slow taper watching carefully for relapse
as the dose is reduced. Repeated relapses, particularly
preventing steroid dose reduction, should be treated
with an additional immunosuppressive agent. The
presence of neurosarcoidosis requires more prolonged
higher-dose treatment with steroids and immunosup-
pression from the outset, with early recourse to bio-
logical agents should the clinical and radiologic
features of the disorder fail to improve quickly.
Further study is required to identify precisely which
treatments are best and over what period of time.
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